American journal of hematology 2020 Dec 08
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
Related Questions
NGS results are pending
New answer by Medical Oncologist at The Ohio State University Comprehensive Cancer Center / James Cancer Hospital and Solove Research Institute (January 25, 2024)
It would be important to know what type of "favorable risk" AML the patients had and also what the current NGS shows. I would wait on NGS results to return to see what the opt...